Base title: prevent preclinical pharmacology and toxicology task order title: nicotine reduction therapy using the human monoclonal antibody ATI-1013
Ended Awarded Last action
- Contract number
- 75N91023F00001
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $656,577
Award facts
- Opportunity
-
- TORFPT05 Solicitation number
- Contract value 100% obligated
- $656,577.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$2,912 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $659,489 |
About this award
This is a $656,577 firm-fixed-price delivery order awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit subsidiary of the Illinois Institute of Technology. The order is for a nicotine reduction therapy using the human monoclonal antibody ATI-1013, under the broader PREVENT Preclinical Drug Development Program (PREVENT). IITRI is conducting preclinical pharmacology and toxicology studies to support the investigational new drug (IND) application for this nicotine reduction therapy. IITRI has extensive experience providing preclinical research services to federal agencies, including NCI, through prime contracts and subcontracts. This task order is not associated with any set-aside designations.
Quick answers
Who was awarded contract 75N91023F00001?
75N91023F00001 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 22, 2023.
How much is contract 75N91023F00001 worth?
The government has obligated $656,577 on 75N91023F00001.
Is contract 75N91023F00001 an order under another contract?
Yes. 75N91023F00001 is a delivery order under 75N91019D00013, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00001 competed?
The extent of competition for 75N91023F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award